research use only
Cat.No.S3732
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV |
|---|---|
| Other β-lactamase Inhibitors | Sultamicillin Clavulanic acid |
|
In vitro |
DMSO
: 57 mg/mL
(198.44 mM)
Water : 57 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 287.23 | Formula | C7H10N3O6 .Na |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1192491-61-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | AVE-1330A, NXL104 | SMILES | C1CC(N2CC1N(C2=O)OS(=O)(=O)[O-])C(=O)N.[Na+] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
SHV-4
(Cell-free assay) 1.5 nM
TEM-1
(Cell-free assay) 8 nM
KPC-2
(Cell-free assay) 38 nM
P99
(Cell-free assay) 80 nM
|
|---|---|
| In vitro |
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. Avibactam has an unusual mechanism of action: it is a covalent inhibitor that acts via ring opening, but in contrast to other currently used β-lactamase inhibitors, this reaction is reversible.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-08-12)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07759453 | NOT_YET_RECRUITING | Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization |
IRCCS Azienda Ospedaliero-Universitaria di Bologna |
2026-10-01 | PHASE3 |
| NCT07004049 | RECRUITING | Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance |
National University of Singapore |
2025-04-21 | PHASE4 |
| NCT07327619 | RECRUITING | Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia |
Qilu Pharmaceutical Co., Ltd. |
2026-01-22 | PHASE3 |
| NCT07634198 | NOT_YET_RECRUITING | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) |
Nanjing Yoko Biomedical Co., Ltd. |
2026-06-04 | PHASE3 |
| NCT07431307 | NOT_YET_RECRUITING | Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial; Ventriculitis, Infectious |
BioVersys AG |
2026-07 | PHASE2 |
| NCT06939829 | NOT_YET_RECRUITING | Patients With Critically Ill Infections |
Southeast University, China |
2025-05-01 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.